Un virus tapi dans l'ombre : les bases moleculaires de la latence du VIH-1 - Partie II : la reactivation de la latence du VIH-1 et ses implications therapeutiques.
Cherrier, Thomas; Le Douce, Valentin; Redel, Laetitiaet al.
[en] The latent HIV-1 reservoirs established early during infection present a major obstacle for virus eradication. Complete eradication of the virus from infected patients may require a purge of the reservoirs. Since the development of a HIV-1 vaccine is not achieved, and therefore remains a major challenge for the immunologists, future direction towards an effective curative therapy for HIV-1 infection will rely on the development of original therapeutic strategies which take into account latency, chronic replication and accessibility to tissue-sanctuary.
Un virus tapi dans l'ombre : les bases moleculaires de la latence du VIH-1 - Partie II : la reactivation de la latence du VIH-1 et ses implications therapeutiques.
Alternative titles :
[en] Molecular basis of HIV-1 latency - Part II: HIV-1 reactivation and therapeutic implications
Williams SA, Greene WC. Regulation of HIV-1 latency by T-cell activation. Cytokine 2007; 39: 63-74.
Narlikar GJ, Fan HY, Kingston RE. Cooperation between complexes that regulate chromatin structure and transcription. Cell 2002; 108: 475-87.
Treand C, Du Chêne I, Bres V, et al. Requirement for SWI/SNF chromatin-remodeling complex in Tatmediated activation of the HIV-1 promoter. EMBO J 2006; 25: 1690-9.
Ganesh L, Burstein E, Guha-Niyogi A, et al. The gene product Murr1 restricts HIV-1 replication in resting CD4+ lymphocytes. Nature 2003; 426: 853-7.
Yeung ML, Benkirane M, Jeang KT. Small non-coding RNAs, mammalian cells, and viruses: regulatory interactions? Retrovirology 2007; 4: 74.
Triboulet R, Benkirane M. Implication de la voie des microARN dans la réplication du VIH. Med Sci (Paris) 2007; 23: 590-2.
Triboulet R, Mari B, Lin YL, et al. Suppression of microRNA-silencing pathway by HIV-1 during virus replication. Science 2007; 315: 1579-82.
Chun TW, Justement JS, Lempicki RA, et al. Gene expression and viral prodution in latently infected, resting CD4+ T cells in viremic versus aviremic HIV-infected individuals. Proc Natl Acad Sci USA 2003; 100: 1908-13.
Corbeau P. Interfering RNA and HIV: reciprocal interferences. PLoS Pathog 2008; 4: e1000162.
Perelson AS, Essunger P, Cao Y, et al. Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 1997; 387: 188-91.
Dornadula G, Zhang H, VanUitert B, et al. Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy. Jama 1999; 282: 1627-32.
Maldarelli F, Palmer S, King MS, et al. ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremia. PLoS Pathog 2007; 3: e46.
Palmer S, Wiegand AP, Maldarelli F, et al. New real-time reverse transcriptase-initiated PCR assay with single-copy sensitivity for human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol 2003; 41: 4531-6.
Shen L, Siliciano RF. Viral reservoirs, residual viremia, and the potential of highly active antiretroviral therapy to eradicate HIV infection. J Allergy Clin Immunol 2008; 122: 22-8.
Bailey JR, Sedaghat AR, Kieffer T, et al. Residual human immunodeficiency virus type 1 viremia in some patients on antiretroviral therapy is dominated by a small number of invariant clones rarely found in circulating CD4+ T cells. J Virol 2006; 80: 6441-57.
Llewellyn N, Zioni R, Zhu H, et al. Continued evolution of HIV-1 circulating in blood monocytes with antiretroviral therapy: genetic analysis of HIV-1 in monocytes and CD4+ T cells of patients with discontinued therapy. J Leukoc Biol 2006; 80: 1118-26.
Cumont MC, Monceaux V, Viollet L, et al. TGF-beta in intestinal lymphoid organs contributes to the death of armed effector CD8 T cells and is associated with the absence of virus containment in rhesus macaques infected with the simian immunodeficiency virus. Cell Death Differ 2007; 14: 1747-58.
Aquaro S, Calio R, Balzarini J, et al. Macrophages and HIV infection: therapeutical approaches toward this strategic virus reservoir. Antiviral Res 2002; 55: 209-25.
Stevens M, De Clercq E, Balzarini J. The regulation of HIV-1 transcription: molecular targets for chemotherapeutic intervention. Med Res Rev 2006; 26: 595-625.
Rohr O, Marban C, Aunis D, Schaeffer E. Regulation of HIV-1 gene transcription: from lymphocytes to microglial cells. J Leukoc Biol 2003; 74: 736-49.
Darbinian-Sarkissian N, Darbinyan A, Otte J, et al. p27(SJ), a novel protein in St John's Wort, that suppresses expression of HIV-1 genome. Gene Ther 2006; 13: 288-95.
Berna A, Bernier F, Chabriere E, Perera T, Scott K. DING proteins; novel members of a prokaryotic phosphate-binding protein superfamily which extends into the eukaryotic kingdom. Int J Biochem Cell Biol 2008; 40: 170-5.
Mok HP, Lever A. Waking Up the Sleepers: HIV Latency and Reactivation. J Formos Med Assoc 2008; 107: 909-14.
Geeraert L, Kraus G, Pomerantz RJ. Hide-and-seek: the challenge of viral persistence in HIV-1 infection. Annu Rev Med 2008; 59: 487-501.
Wang FX, Xu Y, Sullivan J, et al. IL-7 is a potent and proviral strain-specific inducer of latent HIV-1 cellular reservoirs of infected individuals on virally suppressive HAART. J Clin Invest 2005; 115: 128-37.
Chun TW, Engel D, Mizell SB, Ehler LA, Fauci AS. Induction of HIV-1 replication in latently infected CD4+ T cells using a combination of cytokines. J Exp Med 1998; 188: 83-91.
Mai A. The therapeutic uses of chromatin-modifying agents. Expert Opin Ther Targets 2007; 11: 835-51.
Siliciano JD, Lai J, Callender M, et al. Stability of the latent reservoir for HIV-1 in patients receiving valproic acid. J Infect Dis 2007; 195: 833-6.
Contreras X, Barboric M, Lenasi T, Peterlin BM. HMBA releases P-TEFb from HEXIM1 and 7SK snRNA via PI3K/Akt and activates HIV transcription. PLoS Pathog 2007; 3: 1459-69.
Martinez V, Autran B. Les HIV controllers: une nouvelle entité évolutive de l'infection par le VIH ? Med Sci (Paris) 2008; 24: 7-9.
Schwartz C, Le Douce V, Cherrier T, et al. Un virus tapi dans l'ombre: les bases moléculaires de la latence du VIH-1. Partie I: la physiologie de la latence du VIH-1. Med Sci (Paris) 2010; 26: 159-63.